Search - tctmd.com

Displaying 281 - 300 of 1179

Sort: Relevancy | Date

News Daily News

Same-Day Discharge After PCI Is Safe, With Benefits for Patients and Hospitals: Review

Todd Neale

April 01, 2016

News Daily News

美国指南更新，将接受 DES 的稳定患者的 DAPT 持续时间从 12 个月下调为 6 个月

Yael L. Maxwell

March 30, 2016

News Daily News

Updated US Guidelines Lower DAPT Duration From 12 to 6 Months in Stable Patients Receiving DES

Yael L. Maxwell

March 30, 2016

News Daily News

Las Últimas Directrices Norteamericanas Reducen la Duración del Tratamiento Antiplaquetario Doble de 12 a 6 Meses en Pacientes Estables que Reciben un SLF

Yael L. Maxwell

March 30, 2016

News Daily News

Crushed Prasugrel Pills Beat Whole Tablets for Controlling Platelets During Primary PCI

Caitlin E. Cox

March 28, 2016

News Industry News

Aralez Announces FDA Acceptance of New Drug Application for YOSPRALA™

March 28, 2016

News Opinion Editor's Corner

ACC 2016: HOPE for Primary Prevention, TAVR in Moderate-Risk Patients, Deferred Stenting in STEMI, and More

Shelley Wood

March 28, 2016

News Daily News

Evidence Mounts Showing No Increased Risk of Heart Failure With Incretin-Based Antidiabetic Drugs

Michael O'Riordan

March 25, 2016

News Daily News

Novel Oral Anticoagulant for VTE Prevention Misses Primary Endpoint in APEX

Todd Neale

March 24, 2016

News Daily News

Un Nuevo Análisis del COGENT Avala el Uso de PPI en Pacientes con Dosis Bajas de Aspirina

Caitlin E. Cox

March 23, 2016

News Daily News

New Analysis of COGENT Supports PPI Use in Patients on Low-Dose Aspirin

Caitlin E. Cox

March 23, 2016

News Daily News

COGENT 新分析支持对低剂量阿司匹林患者使用 PPI

Caitlin E. Cox

March 23, 2016

Presentation

Proton-Pump Inhibitors (PPIs) Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy

Presenter: Muthia Vaduganathan

March 22, 2016

News Daily News

US Cardiologists Are Underusing Oral Anticoagulation for A-fib

Todd Neale

March 21, 2016

News Daily News

¿Relaja el Acuerdo de la FDA con Amarin el Control de las Promociones Fuera de Indicación?

Michael O'Riordan

March 09, 2016

News Daily News

Will FDA’s Settlement With Amarin Weaken Agency Oversight of Off-Label Promotion?

Michael O'Riordan

March 09, 2016

News Daily News

FDA 与阿玛琳之间的和解是否会减弱该局对标签外用途推广的监督？

Michael O'Riordan

March 09, 2016

News Daily News

Newer-Generation DES With Abbreviated DAPT Bests BMS in Patients at High Risk for Bleeding

L.A. McKeown

March 08, 2016

News Daily News

El Controvertido Ensayo LIGHT Ahora Publicado No Arroja Luz sobre los Riesgos CV de Contrave

Michael O'Riordan

March 08, 2016

News Daily News

Controversial LIGHT Trial Now Published but Fails to Illuminate CV Risks of Contrave

Michael O'Riordan

March 08, 2016

Advertisement

Same-Day Discharge After PCI Is Safe, With Benefits for Patients and Hospitals: Review

美国指南更新，将接受 DES 的稳定患者的 DAPT 持续时间从 12 个月下调为 6 个月

Updated US Guidelines Lower DAPT Duration From 12 to 6 Months in Stable Patients Receiving DES

Las Últimas Directrices Norteamericanas Reducen la Duración del Tratamiento Antiplaquetario Doble de 12 a 6 Meses en Pacientes Estables que Reciben un SLF

Crushed Prasugrel Pills Beat Whole Tablets for Controlling Platelets During Primary PCI

Aralez Announces FDA Acceptance of New Drug Application for YOSPRALA™

ACC 2016: HOPE for Primary Prevention, TAVR in Moderate-Risk Patients, Deferred Stenting in STEMI, and More

Evidence Mounts Showing No Increased Risk of Heart Failure With Incretin-Based Antidiabetic Drugs

Novel Oral Anticoagulant for VTE Prevention Misses Primary Endpoint in APEX

Un Nuevo Análisis del COGENT Avala el Uso de PPI en Pacientes con Dosis Bajas de Aspirina

New Analysis of COGENT Supports PPI Use in Patients on Low-Dose Aspirin

COGENT 新分析支持对低剂量阿司匹林患者使用 PPI

Proton-Pump Inhibitors (PPIs) Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy

US Cardiologists Are Underusing Oral Anticoagulation for A-fib

¿Relaja el Acuerdo de la FDA con Amarin el Control de las Promociones Fuera de Indicación?

Will FDA’s Settlement With Amarin Weaken Agency Oversight of Off-Label Promotion?

FDA 与阿玛琳之间的和解是否会减弱该局对标签外用途推广的监督？

Newer-Generation DES With Abbreviated DAPT Bests BMS in Patients at High Risk for Bleeding

El Controvertido Ensayo LIGHT Ahora Publicado No Arroja Luz sobre los Riesgos CV de Contrave

Controversial LIGHT Trial Now Published but Fails to Illuminate CV Risks of Contrave

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content